International journal of clinical oncology · 2026
Impact of periodontitis on the efficacy of neoadjuvant immunochemotherapy in non-small cell lung cancer: a multi-center real-world study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Ling, Chen Hang, Yin Hui, Shen Yaofeng, Shen Fan, Guo Zimo, Zhai Baixue, Wang Yiping, Kong Weicheng, Xu Guodong, Luo Qingquan, Pan Jinsong, Pan Hanbo
Аннотация
BACKGROUND: Neoadjuvant immunochemotherapy has revolutionized non-small cell lung cancer(NSCLC) treatment. Periodontitis(PD) is one of the most prevalent oral diseases worldwide; however, its influence on the efficacy of neoadjuvant immunochemotherapy in NSCLC remains unclear. This study aimed to evaluate the association between PD status and severity with treatment outcomes following neoadjuvant immunochemotherapy in NSCLC.
METHODS: Patients with initial stage IIA-IIIB NSCLC(excluding T4N2 and N3) who underwent surgery after neoadjuvant immunochemotherapy at three institutions between 2019 and 2025 were retrospectively reviewed. Stabilized inverse probability of treatment weighting(IPTW) was employed to balance baseline characteristics. The primary endpoint was major pathological response(MPR) rates.
RESULTS: A total of 51 non-PD and 331 PD cases were included. After IPTW adjustment, PD was associated with lower MPR(33.5% vs. 43.5%, adjusted P = 0.036) and complete pathological response rates, as well as poorer early survival. Increasing PD severity was identified as an independent risk factor for diminished therapeutic efficacy. Specifically, grade II-III PD, but not grade I PD, was associated with poorer pathological response and preliminary survival outcomes. Interaction analyses revealed that such associative patterns were modified by age and body mass index(BMI). Subsequent stratified analyses confirmed that grade II-III PD was correlated with impaired pathological response and early survival in younger(age < 65 years) and non-overweight(BMI ≤ 24.0 kg/m2) patients, but not in older(age ≥ 65 years) and overweight(BMI > 24.0 kg/m2) patients.
CONCLUSION: PD may be an unfavorable prognostic factor associated with clinical outcomes of neoadjuvant immunochemotherapy in NSCLC. Grade II-III PD may be associated with worse pathological response and early survival, with more pronounced adverse effects in younger and non-overweight patients.
METHODS: Patients with initial stage IIA-IIIB NSCLC(excluding T4N2 and N3) who underwent surgery after neoadjuvant immunochemotherapy at three institutions between 2019 and 2025 were retrospectively reviewed. Stabilized inverse probability of treatment weighting(IPTW) was employed to balance baseline characteristics. The primary endpoint was major pathological response(MPR) rates.
RESULTS: A total of 51 non-PD and 331 PD cases were included. After IPTW adjustment, PD was associated with lower MPR(33.5% vs. 43.5%, adjusted P = 0.036) and complete pathological response rates, as well as poorer early survival. Increasing PD severity was identified as an independent risk factor for diminished therapeutic efficacy. Specifically, grade II-III PD, but not grade I PD, was associated with poorer pathological response and preliminary survival outcomes. Interaction analyses revealed that such associative patterns were modified by age and body mass index(BMI). Subsequent stratified analyses confirmed that grade II-III PD was correlated with impaired pathological response and early survival in younger(age < 65 years) and non-overweight(BMI ≤ 24.0 kg/m2) patients, but not in older(age ≥ 65 years) and overweight(BMI > 24.0 kg/m2) patients.
CONCLUSION: PD may be an unfavorable prognostic factor associated with clinical outcomes of neoadjuvant immunochemotherapy in NSCLC. Grade II-III PD may be associated with worse pathological response and early survival, with more pronounced adverse effects in younger and non-overweight patients.